File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.12688/f1000research.24543.1
- Scopus: eid_2-s2.0-85086875884
- PMID: 32595940
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Hepatocellular carcinoma: recent advances and emerging medical therapies
Title | Hepatocellular carcinoma: recent advances and emerging medical therapies |
---|---|
Authors | |
Keywords | hepatocellular carcinoma medical therapy |
Issue Date | 2020 |
Publisher | Faculty of 1000 Ltd. The Journal's web site is located at http://f1000research.com |
Citation | F1000Research, 2020, v. 9, p. article no. 620 How to Cite? |
Abstract | Hepatocellular carcinoma remains a deadly disease with poor prognosis in patients with unresectable cancer. Trans-arterial chemoembolization is the primary locoregional therapy for intermediate-stage hepatocellular carcinoma, with an estimated median overall survival of less than two years. For almost a decade, sorafenib has been the only standard systemic treatment for metastatic disease or tumors which progress or are considered unsuitable for locoregional therapy. Major breakthroughs have been made over the past few years in the management of hepatocellular carcinoma, especially in medical therapies for advanced disease. In this article, recent advances in intra-arterial therapy, multi-kinase inhibitors, and immunotherapy will be reviewed. |
Persistent Identifier | http://hdl.handle.net/10722/284983 |
ISSN | 2020 SCImago Journal Rankings: 1.099 |
PubMed Central ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ko, KL | - |
dc.contributor.author | Mak, LY | - |
dc.contributor.author | Cheung, KS | - |
dc.contributor.author | Yuen, MF | - |
dc.date.accessioned | 2020-08-07T09:05:11Z | - |
dc.date.available | 2020-08-07T09:05:11Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | F1000Research, 2020, v. 9, p. article no. 620 | - |
dc.identifier.issn | 2046-1402 | - |
dc.identifier.uri | http://hdl.handle.net/10722/284983 | - |
dc.description.abstract | Hepatocellular carcinoma remains a deadly disease with poor prognosis in patients with unresectable cancer. Trans-arterial chemoembolization is the primary locoregional therapy for intermediate-stage hepatocellular carcinoma, with an estimated median overall survival of less than two years. For almost a decade, sorafenib has been the only standard systemic treatment for metastatic disease or tumors which progress or are considered unsuitable for locoregional therapy. Major breakthroughs have been made over the past few years in the management of hepatocellular carcinoma, especially in medical therapies for advanced disease. In this article, recent advances in intra-arterial therapy, multi-kinase inhibitors, and immunotherapy will be reviewed. | - |
dc.language | eng | - |
dc.publisher | Faculty of 1000 Ltd. The Journal's web site is located at http://f1000research.com | - |
dc.relation.ispartof | F1000Research | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | hepatocellular carcinoma | - |
dc.subject | medical therapy | - |
dc.title | Hepatocellular carcinoma: recent advances and emerging medical therapies | - |
dc.type | Article | - |
dc.identifier.email | Mak, LY: lungyi@hku.hk | - |
dc.identifier.email | Cheung, KS: cks634@hku.hk | - |
dc.identifier.email | Yuen, MF: mfyuen@hku.hk | - |
dc.identifier.authority | Mak, LY=rp02668 | - |
dc.identifier.authority | Cheung, KS=rp02532 | - |
dc.identifier.authority | Yuen, MF=rp00479 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.12688/f1000research.24543.1 | - |
dc.identifier.pmid | 32595940 | - |
dc.identifier.pmcid | PMC7308880 | - |
dc.identifier.scopus | eid_2-s2.0-85086875884 | - |
dc.identifier.hkuros | 312203 | - |
dc.identifier.volume | 9 | - |
dc.identifier.spage | article no. 620 | - |
dc.identifier.epage | article no. 620 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 2046-1402 | - |